An exploratory study of the biologic effects of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) treatment in patients (pts) with advanced (unresectable or metastatic) melanoma (MEL).
Year: 2013
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Jeffrey Alan Sosman, Salvador Martin-Algarra, Jedd D. Wolchok, William Howard Sharfman, Shailender Bhatia, F. Stephen Hodi, Wen-Jen Hwu, Thomas Gajewski, Craig L. Slingluff, Howard Kaufman, Manish Gupta, Analia McGirr, Christine E. Horak, Christoph Matthias Ahlers, Jon M. Wigginton, Walter John Urba
Institutions: Vanderbilt University, Vanderbilt-Ingram Cancer Center, Universidad de Navarra, Memorial Sloan Kettering Cancer Center, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, University of Washington, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, The University of Texas MD Anderson Cancer Center, University of Chicago, University of Virginia, Rush University Medical Center, Bristol-Myers Squibb (United States), Providence Portland Medical Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2247601177